Close

CytRx (CYTR) Announces Positive Updated on Phase 2 Aldoxorubicin Trial

May 21, 2015 9:02 AM EDT Send to a Friend
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced positive updated results from its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login